Negative in Ames, in vitro human lymphocyte chromosome aberration and rat micronucleus assays
“Amisulpride was negative in the Ames test, the in vitro mammalian chromosome aberration assay in human peripheral blood lymphocytes and the in vivo micronucleus assay in rats by oral gavage.”
✓ VerifiedFDA multi-discipline review, p. 60Source ↗
Carcinogenicity
Not conducted; not required for a single-dose indication
“Carcinogenicity studies of amisulpride were not conducted. Carcinogenicity studies are not required for this indication for which the drug will be administered as a single dose.”
✓ VerifiedFDA multi-discipline review, p. 70Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat fertility: most females (90-95%) stayed in diestrus and failed to mate; effect reversed after treatment stopped
“Most female animals (90% to 95%) at each dose level remained in diestrus and failed to mate. However, this effect on mating reversed following cessation of treatment.”
hERG IC50 ~100 µM, suggesting a low risk of clinical QT prolongation
“In an in vitro hERG assay, amisulpride showed hERG channel inhibitory effects with an IC50 of ~100μM, suggesting a low risk for clinical QT prolongation.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗
Genotox: Ames
Negative
“Amisulpride had no mutagenic potential in the Bacterial Reverse Mutation Assay.”
✓ VerifiedFDA multi-discipline review, p. 67Source ↗
Genotox: in vitro mammalian
Chromosome aberration in human peripheral blood lymphocytes: negative
“Amisulpride was negative in the Ames test, the in vitro mammalian chromosome aberration assay in human peripheral blood lymphocytes and the in vivo micronucleus assay in rats by oral gavage.”
✓ VerifiedFDA multi-discipline review, p. 60Source ↗
Genotox: in vivo
Rat micronucleus (oral): negative up to 300 mg/kg/day
“Amisulpride was negative in the in vivo micronucleus assay in rats at oral doses up to 300 mg/kg/day.”
✓ VerifiedFDA multi-discipline review, p. 69Source ↗
Carcinogenicity model
Not conducted (single-dose indication)
“Carcinogenicity studies of amisulpride were not conducted. Carcinogenicity studies are not required for this indication for which the drug will be administered as a single dose.”
✓ VerifiedFDA multi-discipline review, p. 70Source ↗
Carcinogenicity timing
Not required: single-dose indication; not conducted
“Carcinogenicity studies of amisulpride were not conducted. Carcinogenicity studies are not required for this indication for which the drug will be administered as a single dose.”
✓ VerifiedFDA multi-discipline review, p. 70Source ↗
hERG / QT
hERG IC50 ~100 µM; low risk of clinical QT prolongation
“In an in vitro hERG assay, amisulpride showed hERG channel inhibitory effects with an IC50 of ~100μM, suggesting a low risk for clinical QT prolongation.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative